SSSoumitra SamantaMSc, MTech, PhDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Integration of Machine Learning for Predictive Pharmacometric Assessments - Soumitra SamantaView Slideset
ERElias RosenPhDSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #21 Longitudinal Monitoring of Cabotegravir and Rilpivirine Exposure from Hair Strand Concentrations - Elias RosenView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #20 An Enzymatic Assay with Lateral Flow Readout for Measurement of Tenofovir Diphosphate and Long-Term HIV Medication Adherence - Carrie LinView Slideset
SlidesetHIVViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #19 Assessing ChatGPT’s Capability in Understanding and Reporting Antiretroviral Therapy Drug-Drug Interaction Effects: Quantitative and Qualitative Results from the ACCURATE-DDI Study - Erin ReadyView Slideset
JCJon CollinsPharmDSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #17 Lack of Clinically Significant Drug–Drug Interactions Between the Third-Generation Integrase Strand Transfer Inhibitor VH4524184 (VH-184) and Combined Oral Contraceptives - Jon CollinsView Slideset
AOAndrew OwenBSS, MSC, PhD, FSBSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #35 Can Low-Cost Oral Alternatives Be Used in Place of Oral Lenacapavir When Initiating Long-Acting Lenacapavir PrEP in Low- and Middle-Income Countries? - Andrew OwenView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #16 Inter- and Intraindividual Variability of Long-Acting Cabotegravir/Rilpivirine Pharmacokinetics after 1 Year of Continuous Use - Shawnalyn SunagawaView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #15 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adolescents Living with HIV-1 in Sub-Saharan Africa: Data from the LATA Trial - Lisanne BeversView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #14 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Seminal Plasma throughout the Dosing Interval - Noah NeveretteView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #13 Intracellular Carbovir- and Lamivudine-Triphosphate Concentrations in PBMC and DBS among Children with HIV-1 Receiving ABC/DTG/3TC: Results from IMPAACT 2019 - Stefanie SchwabView Slideset
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #12 Pharmacokinetics of Abacavir and Lamivudine in Infants with and without Rifampicin Co-Treatment - Laize BecaView Slideset
SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #11 A Preliminary Analysis of the Impact of Pharmacogenetic Variation on Bictegravir and Dolutegravir Concentrations in Individuals with HIV and Tuberculosis - Anushka NaidooView Slideset
